Key result
Antiangiogenic antitumour agents frequently induce arterial hypertension, requiring regular monitoring and prompt antihypertensive treatment to prevent dose reduction or discontinuation of cancer therapy.
Why the study?
Angiogenesis inhibitors increase cardiovascular toxicity, with arterial hypertension being the primary adverse effect limiting doses, prompting the 2022 ESC recommendations on antitumor cardiotoxicity.
Active monitoring and management of arterial hypertension induced by antiangiogenic therapy using standard antihypertensive agents is essential to prevent cardiovascular complications and allow continuation of optimal cancer treatment.
Hypertension monitoring is essential with anti-VEGF agents; leaves open its validity as an efficacy surrogate.
The use of angiogenesis inhibitors (anti-VGEF antibodies and tyrosine kinase inhibitors) in oncology significantly increases both the tumor response to therapy and the risk of cardiovascular toxicity. Arterial hypertension is the main adverse effect of antiangiogenic therapy frequently limiting the doses of angiogenesis inhibitors, although it is also considered as a possible surrogate marker of the effectiveness of targeted therapy. In 2022, the recommendations of the European Society of Cardiology on the prevention and correction of cardiotoxicity of antitumor therapy were published. The article reviews the current diagnosis and treatment of arterial hypertension induced by antiangiogenic medicines.
No takes yet. Share an insight, caveat, or question.
Shavarova et al. (2023) conducted a review in Arterial hypertension induced by antiangiogenic antitumour agents. Antiangiogenic antitumour agents was evaluated. Antiangiogenic antitumour agents frequently induce arterial hypertension, requiring regular monitoring and prompt antihypertensive treatment to prevent dose reduction or discontinuation of cancer therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: